258 related articles for article (PubMed ID: 11607043)
1. Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist.
Nadal R
CNS Drug Rev; 2001; 7(3):265-82. PubMed ID: 11607043
[TBL] [Abstract][Full Text] [Related]
2. Neuropharmacological and behavioural properties of remoxipride in the rat.
Ogren SO; Florvall L; Hall H; Magnusson O; Angeby-Möller K
Acta Psychiatr Scand Suppl; 1990; 358():21-6. PubMed ID: 1978483
[TBL] [Abstract][Full Text] [Related]
3. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
[TBL] [Abstract][Full Text] [Related]
4. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
Ogren SO; Hall H; Köhler C; Magnusson O; Lindbom LO; Angeby K; Florvall L
Eur J Pharmacol; 1984 Jul; 102(3-4):459-74. PubMed ID: 6149133
[TBL] [Abstract][Full Text] [Related]
5. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
6. Selective dopamine D2 antagonist and prolactin response in acute schizophrenia--results from remoxipride studies. The Canadian Remoxipride Study Group.
Awad AG; Lapierre YD; Jostell KG
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):769-77. PubMed ID: 2149882
[TBL] [Abstract][Full Text] [Related]
7. Effects of remoxipride and raclopride on prolactin release from clonal pituitary tumour cells.
Nilsson CL; Eriksson E
Pharmacol Toxicol; 1995 Jan; 76(1):85-8. PubMed ID: 7753765
[TBL] [Abstract][Full Text] [Related]
8. Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys.
Gerlach J; Casey DE
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):103-12. PubMed ID: 1967845
[TBL] [Abstract][Full Text] [Related]
9. Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia.
Wadworth AN; Heel RC
Drugs; 1990 Dec; 40(6):863-79. PubMed ID: 1981869
[TBL] [Abstract][Full Text] [Related]
10. Effects of the atypical antipsychotic remoxipride on alcohol self-administration.
Files FJ; Denning CE; Samson HH
Pharmacol Biochem Behav; 1998 Feb; 59(2):281-5. PubMed ID: 9476971
[TBL] [Abstract][Full Text] [Related]
11. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
Busatto GF; Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Kerwin RW
Psychopharmacology (Berl); 1995 Jan; 117(1):55-61. PubMed ID: 7536945
[TBL] [Abstract][Full Text] [Related]
12. [Remoxipride, a selective antagonist of dopamine D2 receptors, in the treatment of delusional psychoses].
Lewander T; Westerberg SE; Ogren SO; Von Bahr C; Köhler C
Encephale; 1990; 16(2):153-7. PubMed ID: 1972054
[TBL] [Abstract][Full Text] [Related]
13. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent].
Ogren SO; Hall H; Köhler C; Magnusson O; Florvall L
Arzneimittelforschung; 1985; 35(8):1227-31. PubMed ID: 2866774
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of the dopamine antagonist remoxipride on apomorphine induced behaviour in the rat.
Ståhle L; Ljungberg T; Rodebjer A; Ogren SO; Ungerstedt U
Pharmacol Toxicol; 1987 Mar; 60(3):227-32. PubMed ID: 2884654
[TBL] [Abstract][Full Text] [Related]
15. Prototypical antipsychotic drugs protect hippocampal neuronal cultures against cell death induced by growth medium deprivation.
Bastianetto S; Danik M; Mennicken F; Williams S; Quirion R
BMC Neurosci; 2006 Mar; 7():28. PubMed ID: 16573831
[TBL] [Abstract][Full Text] [Related]
16. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of latent inhibition in the rat by the atypical antipsychotic agent remoxipride.
Trimble KM; Bell R; King DJ
Pharmacol Biochem Behav; 1997 Apr; 56(4):809-16. PubMed ID: 9130309
[TBL] [Abstract][Full Text] [Related]
18. Remoxipride shows low propensity to block functional striatal dopamine D2 receptors in vitro.
Westlind-Danielsson A; Gustafsson K; Andersson I
Eur J Pharmacol; 1994 Dec; 288(1):89-95. PubMed ID: 7705472
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of remoxipride and raclopride on nigrostriatal and mesolimbic dopaminergic neuronal activity and on the secretion of prolactin and alpha-melanocyte-stimulating hormone.
Eaton MJ; Tian Y; Lookingland KJ; Moore KE
Neuropsychopharmacology; 1992 Nov; 7(3):205-11. PubMed ID: 1326981
[TBL] [Abstract][Full Text] [Related]
20. Biochemical pharmacology of the atypical neuroleptic remoxipride.
Köhler C; Hall H; Magnusson O; Lewander T; Gustafsson K
Acta Psychiatr Scand Suppl; 1990; 358():27-36. PubMed ID: 1978484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
